Evaluation of high dose of perindopril/indapamide fixed combination in reducing blood pressure and improving end-organ protection in hypertensive patients

References

• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Gosse P, Gueret P, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23:2063-70
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• Mourad JJ, Waeber B, Zannad F, et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004;22:2379-86
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Naditch-Brule L, Perlini S, et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008;26:2064-70
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40
   PubMed Web of Science ®Google Scholar
• Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008;26:1505-26
   PubMed Web of Science ®Google Scholar
• Mallion JM, Chamontin B, Asmar R, et al. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. Am J Hypertens 2004;17:245-51
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003;41:1063-71
   PubMed Web of Science ®Google Scholar
• Chalmers J, Joshi R, Kengne AP, MacMahon S. Blood pressure lowering with fixed combination perindopril-indapamide: key findings from ADVANCE. J Hypertens Suppl 2008;26:S11-15
   PubMedGoogle Scholar
• ADVANCE – Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med 2005;22:882-8
   PubMed Web of Science ®Google Scholar
• Neglia D, Fommei E, Ghione S, et al. P727: coronary microvascular dysfunction in hypertensive patients with left ventricular hypertrophy can be reversed by treatment with a fixed combination of perindropril and indapamide. Eur Heart J 2008;29(Abstr Suppl):103
   Web of Science ®Google Scholar
• Mourad JJ, Hanon O, Deverre JR, et al. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst 2003;4:94-5
   PubMed Web of Science ®Google Scholar
• Asmar RG, London GM, O'Rourke ME, et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001;38:922-6
   PubMed Web of Science ®Google Scholar
• de Galan B, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-92
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98
   PubMed Web of Science ®Google Scholar
• Myers MG, Asmar R, Leenen FH, et al. Fixed low-dose combination therapy in hypertension – a dose response study of perindopril and indapamide. J Hypertens 2000;18:317-25
   PubMed Web of Science ®Google Scholar
• Mourad JJ, Le Jeune S. High dose of perindopril/indapamide (8/2.5mg) fixed combination is more effective in reducing blood pressure and left ventricular hypertrophy in hypertensive patients. In: European Society of Hypertension 2009, June 12--16; Milan, Italy
   Google Scholar
• Gosse P. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection. Expert Rev Cardiovasc Ther 2006;4:319-33
   PubMedGoogle Scholar
• Kang S, Wu YF, An N, et al. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension. Clin Ther 2004;26:257-70
   PubMed Web of Science ®Google Scholar
• BI PRETERAX® 4mg/1.5mg tablet. European summary of product characteristics. Servier International, Neuilly sur Seine, France. 11/2002
   Google Scholar
• PRETERAX® 2mg/0.625mg tablet. European summary of product characteristics. Servier International, Neuilly sur Seine, France. 11/2003
   Google Scholar
• Zillich J, Garg J, Basu S. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219-24
   PubMed Web of Science ®Google Scholar